U.S. Trade Representative Jamieson Greer said the Trump Administration excluded pharmaceuticals and semiconductors from reciprocal tariffs ...

CRISTIANO AMON, PRESIDENT AND CEO, QUALCOMM Chip-making giant Qualcomm (NASDAQ:QCOM) derived 46% of its ... RICKS, CEO, ELI LILLY Eli Lilly (NYSE:LLY) secured approvals for weight-loss drug ...

Eli Lilly (LLY) stock gains as Goldman Sachs upgrades it to Buy from Neutral citing the company's leadership position in the ...

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for ...

Some neurologists and a consumer watchdog worry that an Eli Lilly–affiliated direct-to-consumer telehealth platform for ...

Eli Lilly is developing what could be the first oral GLP-1 agonist. Late-stage clinical trial data is coming this year. The stock has a steep valuation despite trading sideways since the summer.

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...